Zerion Pharma A/S — Credit Rating and Financial Key Figures
CVR number: 40169229
Fruebjergvej 3, 2100 København Ø
jdh@zerion.eu
tel: 40968018
www.zerion.eu
Income statement (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | 1 189.90 | 1 932.77 | 3 273.33 | 3 559.96 | |
| Other operating income | 1 100.00 | 1 680.00 | 67.75 | ||
| Purchases during the financial year | -2 530.33 | -5 179.06 | -8 351.67 | -5 085.67 | |
| External services | -1 505.62 | -5 148.39 | -5 902.06 | -3 727.68 | |
| Gross profit | - 681.00 | -1 746.05 | -6 714.67 | -10 912.65 | -5 253.39 |
| Employee benefit expenses | - 658.00 | -1 993.45 | -6 245.37 | -9 538.15 | -6 156.56 |
| Other operating expenses | -8.00 | ||||
| Total depreciation | -0.66 | - 219.90 | - 441.03 | - 537.20 | |
| EBIT | -1 347.00 | -3 740.15 | -13 179.94 | -20 891.83 | -11 947.15 |
| Other financial income | 5.28 | 3.83 | 2.97 | ||
| Other financial expenses | -1.00 | - 271.27 | - 571.13 | -1 241.10 | -1 561.47 |
| Pre-tax profit | -1 348.00 | -4 011.42 | -13 745.79 | -22 129.10 | -13 505.64 |
| Income taxes | 297.00 | 533.77 | 2 611.74 | 3 271.78 | 2 403.75 |
| Net earnings | -1 051.00 | -3 477.65 | -11 134.05 | -18 857.32 | -11 101.89 |
Assets (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 802.63 | 2 114.47 | 2 945.73 | 2 625.90 | |
| Tangible assets total | 802.63 | 2 114.47 | 2 945.73 | 2 625.90 | |
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 595.15 | 595.01 | 818.19 | 492.33 | |
| Prepayments and accrued income | 99.28 | 578.73 | 76.18 | ||
| Current other receivables | 158.00 | 888.67 | 1 153.18 | 1 161.76 | 467.83 |
| Current deferred tax assets | 297.00 | 665.41 | 2 611.74 | 3 393.96 | 2 510.00 |
| Short term receivables total | 455.00 | 2 248.51 | 4 938.67 | 5 373.91 | 3 546.33 |
| Cash and bank deposits | 580.00 | 3 948.61 | 6 644.49 | 4 103.62 | 2 299.97 |
| Cash and cash equivalents | 580.00 | 3 948.61 | 6 644.49 | 4 103.62 | 2 299.97 |
| Balance sheet total (assets) | 1 035.00 | 6 999.75 | 13 697.62 | 12 423.25 | 8 472.21 |
Equity and liabilities (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 91.00 | 102.25 | 459.48 | 520.93 | 640.02 |
| Share premium account | 991.00 | ||||
| Retained earnings | 2 346.30 | 9 807.74 | 8 378.31 | -3 268.64 | |
| Profit of the financial year | -1 051.00 | -3 477.65 | -11 134.05 | -18 857.32 | -11 101.89 |
| Shareholders equity total | 31.00 | -1 029.11 | - 866.83 | -9 958.08 | -13 730.51 |
| Non-current loans from credit institutions | 6 198.43 | 10 403.83 | 17 768.02 | 19 196.38 | |
| Non-current other liabilities | 500.00 | ||||
| Non-current deferred tax liabilities | 175.65 | 175.65 | 181.00 | 187.70 | |
| Non-current liabilities total | 500.00 | 6 374.08 | 10 579.47 | 17 949.02 | 19 384.08 |
| Current loans from credit institutions | 537.50 | 837.99 | 922.49 | ||
| Current trade creditors | 391.00 | 760.48 | 2 366.48 | 1 987.24 | 1 536.08 |
| Other non-interest bearing current liabilities | 113.00 | 356.80 | 1 618.50 | 1 607.08 | 360.07 |
| Current liabilities total | 504.00 | 1 654.78 | 3 984.98 | 4 432.31 | 2 818.64 |
| Balance sheet total (liabilities) | 1 035.00 | 6 999.75 | 13 697.62 | 12 423.25 | 8 472.21 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.